Table 2 List of outcome categories/outcomes in COS from the included studies by study type
Outcome classification/Outcomes | All COS studies (n = 11); | COS for clinical trials or clinical research (n = 8) | COS for practice (n = 2) | COS/patient reported outcomes (n = 1) | ||||
|---|---|---|---|---|---|---|---|---|
No. O | No. S | No. O | No. S | No. O | No. S | No. O | No. S | |
Mortality and survival | 18 | 8 | 15 | 6 | 3 | 2 | NA | NA |
Survival | 2 | 2 | 0 | NA | ||||
Overall survival | 5 | 3 | 2 | NA | ||||
Cause- (or disease) specific survival | 6 | 5 | 1 | NA | ||||
Relative survival | 1 | 1 | 0 | NA | ||||
Metastasis-free survival | 2 | 2 | 0 | NA | ||||
Progression-free survival | 1 | 1 | 0 | NA | ||||
Biochemical recurrence-free survival | 1 | 1 | 0 | NA | ||||
Outcomes relating to neoplasms | 19 | 7 | 18 | 6 | 1 | 1 | 0 | 0 |
(Change in) prostate-specific antigen (PSA) levels | 3 | 3 | 0 | 0 | ||||
Measurable disease response | 1 | 1 | 0 | 0 | ||||
Time to progression | 2 | 2 | 0 | 0 | ||||
Disease progression/Progression rate | 2 | 2 | 0 | 0 | ||||
Progression-free probability | 1 | 1 | 0 | 0 | ||||
Development of metastases | 1 | 1 | 0 | 0 | ||||
Metastases-free probability | 1 | 1 | 0 | 0 | ||||
Symptomatic skeletal event | 1 | 0 | 1 | 0 | ||||
Local disease | 1 | 1 | 0 | 0 | ||||
Positive surgical margins | 1 | 1 | 0 | 0 | ||||
Response duration | 1 | 1 | 0 | 0 | ||||
Failure-free probability | 1 | 1 | 0 | 0 | ||||
Development of castration-resistant disease | 1 | 1 | 0 | 0 | ||||
Treatment failure | 2 | 2 | 0 | 0 | ||||
Renal and urinary outcomes | 13 | 6 | 8 | 3 | 3 | 2 | 2 | 1 |
Urinary incontinence | 4 | 2 | 1 | 1 | ||||
Urinary obstruction/irritation | 3 | 1 | 1 | 1 | ||||
Urinary symptoms | 1 | 0 | 1 | 0 | ||||
Voiding behaviour | 1 | 1 | 0 | 0 | ||||
Haematuria | 1 | 1 | 0 | 0 | ||||
Pelvic pain | 1 | 1 | 0 | 0 | ||||
Lymphedema | 1 | 1 | 0 | 0 | ||||
Urinary functioning | 1 | 1 | 0 | 0 | ||||
Gastrointestinal outcomes | 6 | 5 | 3 | 2 | 2 | 2 | 1 | 1 |
Bowel symptoms | 3 | 0 | 2 | 1 | ||||
Faecal incontinence | 1 | 1 | 0 | 0 | ||||
Bowel functioning | 1 | 1 | 0 | 0 | ||||
Diarrhoea | 1 | 1 | 0 | 0 | ||||
Endocrine outcomes | 3 | 3 | 0 | 0 | 2 | 2 | 1 | 1 |
Hormonal symptoms | 3 | 0 | 2 | 1 | ||||
Reproductive system outcomes | 6 | 6 | 3 | 3 | 2 | 2 | 1 | 1 |
Erectile/sexual function | 2 | 2 | 0 | 0 | ||||
Erectile/sexual dysfunction (impotence) | 3 | 1 | 1 | 1 | ||||
Sexual symptoms | 1 | 0 | 1 | 0 | ||||
General outcomes | 8 | 3 | 3 | 1 | 3 | 1 | 2 | 1 |
Pain | 2 | 0 | 1 | 1 | ||||
Fatigue | 2 | 0 | 1 | 1 | ||||
Bone pain | 1 | 1 | 0 | 0 | ||||
Weight loss | 1 | 1 | 0 | 0 | ||||
Anaemia | 1 | 1 | 0 | 0 | ||||
Performance status | 1 | 0 | 1 | 0 | ||||
Physical functioning | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
Physical wellbeing/functioning | 3 | 1 | 1 | 1 | ||||
Emotional functioning/wellbeing | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 |
Mental/emotional wellbeing/functioning | 4 | 2 | 1 | 1 | ||||
Social functioning | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
Social functioning | 1 | 1 | 0 | 0 | ||||
Role functioning | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
Role functioning | 1 | 1 | 0 | 0 | ||||
Global quality of life | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 |
Quality of life | 6 | 6 | 0 | 0 | ||||
Economic outcomes | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
Cost-effectiveness | 1 | 1 | 0 | 0 | ||||
Costs | 1 | 1 | 0 | 0 | ||||
Need for intervention | 4 | 2 | 2 | 1 | 2 | 1 | 0 | 0 |
Need for salvage therapy | 1 | 1 | 0 | 0 | ||||
Need for curative treatment | 1 | 1 | 0 | 0 | ||||
Need for pain medication | 1 | 0 | 1 | 0 | ||||
Procedures need for local progression | 1 | 0 | 1 | 0 | ||||
Delivery of care | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
Time to treatment failure | 1 | 1 | 0 | 0 | ||||
Adverse events/effects | 8 | 6 | 6 | 4 | 2 | 2 | 0 | 0 |
Adverse events | 3 | 2 | 1 | 0 | ||||
Perioperative deaths | 1 | 1 | 0 | 0 | ||||
Thromboembolic disease | 1 | 1 | 0 | 0 | ||||
Bothersome or symptomatic urethral or anastomotic stricture | 1 | 1 | 0 | 0 | ||||
Side-effects of hormonal therapy | 1 | 1 | 0 | 0 | ||||
Major systemic therapy effects | 1 | 0 | 1 | 0 | ||||
Total | 103 | 72 | 22 | 9 | ||||